Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review

  title={Efficacy of Human Papillomavirus Vaccines: A Systematic Quantitative Review},
  author={L. Medeiros and D. D. Rosa and M. I. da Rosa and M. Bozzetti and R. R. Zanini},
  journal={International Journal of Gynecologic Cancer},
  pages={1166-1176 - 1166-1176}
  • L. Medeiros, D. D. Rosa, +2 authors R. R. Zanini
  • Published 2009
  • Medicine
  • International Journal of Gynecologic Cancer
  • Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide. Two vaccines have been recently evaluated in randomized controlled trials: the bivalent vaccine for HPV 16 and 18 (Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and the quadrivalent vaccine for HPV 6, 11, 16, and 18 (Gardasil, Merck and Co, Inc, Whitehouse Station, NJ). We have performed a systematic review of all randomized controlled trials in which vaccines against HPV were compared with… CONTINUE READING
    74 Citations
    Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    • 9
    • PDF
    The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
    The two faces of human papillomavirus.
    • 1


    Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    • 1,712
    • PDF
    A controlled trial of a human papillomavirus type 16 vaccine.
    • 1,717
    Papillomavirus vaccines in perspective
    • 53
    Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
    • 31
    • Highly Influential